Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists

被引：10

作者：

Ogawa, Anthony K. ^{[1
]}

Bunte, Ellen Vande ^{[1
]}

Mal, Rudrajit ^{[1
]}

Lan, Ping ^{[1
]}

Sun, Zhongxiang ^{[1
]}

Crespo, Alejandro ^{[2
]}

Wiltsie, Judyann ^{[1
]}

Clemas, Joseph ^{[1
]}

Gibson, Jack ^{[1
]}

Contino, Lisa ^{[1
]}

Lisnock, JeanMarie ^{[1
]}

Zhou, Gaochao ^{[1
]}

Garcia-Calvo, Margarita ^{[1
]}

Jochnowitz, Nina ^{[1
]}

Ma, Xiuying ^{[1
]}

Pan, Yi ^{[1
]}

Brown, Patricia ^{[1
]}

Zamlynny, Beata ^{[1
]}

Bateman, Thomas ^{[1
]}

Leung, Dennis ^{[2
]}

Xu, Ling ^{[2
]}

Tong, Xinchun ^{[2
]}

Liu, Kun ^{[1
]}

Crook, Martin ^{[1
]}

Sinclair, Peter ^{[1
]}

机构：

[1] Merck & Co Inc, Early Dev & Discovery Sci, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA

[2] Merck & Co Inc, Early Dev & Discovery Sci, 126 E Lincoln Ave, Rahway, NJ 07065 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2016年 / 26卷 / 12期

关键词：

Mineralocorticoid receptor antagonist; Hypertension; Spironolactone; Eplerenone; MILD PATIENTS HOSPITALIZATION; ALDOSTERONE; EPLERENONE; POTENT; IDENTIFICATION; HYPERKALEMIA; SURVIVAL;

D O I：

10.1016/j.bmcl.2016.04.052

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Reported herein are a series of reverse indoles that represent novel non-steroidal mineralocorticoid receptor (MR) antagonists. The key structure-activity relationships (SAR) are presented below. This reverse indole series is exemplified by a compound that demonstrated efficacy in an acute natriuresis rodent model comparable to marketed MR antagonists, spironolactone and eplerenone. (C) 2016 Elsevier Ltd. All rights reserved.

引用

下载

页码：2866 / 2869

页数：4

共 50 条

[41] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Arai, Kiyoshi
Homma, Tsuyoshi
Morikawa, Yuka
Ubukata, Naoko
Tsuruoka, Hiyoyuki
Aoki, Kazumasa
Ishikawa, Hirokazu
Mizuno, Makoto
Sada, Toshio
EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 : 226 - 234
[42] Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists
Yang, Christine
Shen, Hong C.
Wu, Zhicai
Chu, Hong D.
Cox, Jason M.
Balsells, Jaume
Crespo, Alejandro
Brown, Patricia
Zamlynny, Beata
Wiltsie, Judyann
Clemas, Joseph
Gibson, Jack
Contino, Lisa
Lisnock, JeanMarie
Zhou, Gaochao
Garcia-Calvo, Margarita
Bateman, Tom
Xu, Ling
Tong, Xinchun
Crook, Martin
Sinclair, Peter
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (15) : 4388 - 4392
[43] Discovery of Benzimidazole Oxazolidinediones as Novel and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
Yang, Christine
Balsells, Jaume
Chu, Hong D.
Cox, Jason M.
Crespo, Alejandro
Ma, Xiuying
Contino, Lisa
Brown, Patricia
Gao, Sheng
Zamlynny, Beata
Wiltsie, Judyann
Clemas, Joseph
Lisnock, Jean Marie
Gibson, Jack
Zhou, Gaochao
Garcia-Calvo, Margarita
Bateman, Thomas J.
Tong, Vincent
Xu, Ling
Crook, Martin
Sinclair, Peter
Shen, Hong C.
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 461 - 465
[44] Characterization of a novel non-steroidal glucocorticoid receptor antagonist
Li, Qun-Yi
Zhang, Meng
Hallis, Tina M.
DeRosier, Therese A.
Yue, Jian-Min
Ye, Yang
Mais, Dale E.
Wang, Ming-Wei
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 391 (03) : 1531 - 1536
[45] Discovery of AZD9977: A non-steroidal mineralocorticoid modulator for treatment of diabetic kidney disease
Granberg, Kenneth
Yuan, Zhong-Qing
Lindmark, Bo
Edman, Karl
Bamberg, Krister
Hogner, Anders
Kajanus, Johan
Malmgren, Marcus
Lofberg, Christian
Nordqvist, Anneli
Lindberg, Jan
Branalt, Jonas
OMahony, Gavin
Kossenjans, Michael
Liu, Dongmei
Aagaard, Anna
Billger, Martin
Backstrom, Stefan
Cornwall, Philip
Ericsson, Hans
Erlandsson, Fredrik
Hansson, Eva
Hayen, Ahlke
Hermansson, Majlis
Ivarsson, Ida
Lofmark, Rasmus Jansson
Johansson, Ulrika
Karlsson, Ulla
Li, Xueqing
Nikitidis, Grigorios
Nordberg, Peter
Nordin, Andreas
Polentarutti, Britta
Selmi, Nidhal
Turner, Andrew
William-Olsson, Lena
Wingolf, Caroline
Hartleib, Judith
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[46] The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Ulrich Kintscher
Frank Edelmann
Cardiovascular Diabetology, 22
[47] The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Kintscher, Ulrich
Edelmann, Frank
CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
[48] Severe early-onset hypertension induced by a mineralocorticoid receptor (MR) gain-of-function mutation: differential effects of steroidal versus non-steroidal antagonists
Kolkhof, P.
Hillisch, A.
Schaefer, S.
EUROPEAN HEART JOURNAL, 2007, 28 : 769 - 769
[49] Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
Yamada, Makiko
Takei, Makoto
Suzuki, Eiko
Takakusa, Hideo
Kotsuma, Masakatsu
Washio, Takuo
Murayama, Nobuyuki
Inoue, Shin-ichi
Izumi, Takashi
XENOBIOTICA, 2017, 47 (12) : 1090 - 1103
[50] Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy
Grune, Jana
Benz, Verena
Brix, Sarah
Ban, Zsofia
Salatzki, Janek
Hoeft, Beata
Foryst-Ludwig, Anna
Klopfleisch, Robert
Kolkhof, Peter
Kintscher, Ulrich
HYPERTENSION, 2014, 64

← 1 2 3 4 5 →